Lucid Diagnostics Inc. Selling and Marketing Expense
Lucid Diagnostics Inc. (LUCD) reported Selling and Marketing Expense of $5.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-12
- Lucid Diagnostics Inc. selling and marketing expense for the quarter ending 2026-06-30 was $5.78M, a 44.15% increase year-over-year.
- Lucid Diagnostics Inc. selling and marketing expense for the quarter ending 2026-03-31 was $5.00M, a 22.93% increase year-over-year.
- Lucid Diagnostics Inc. selling and marketing expense for the quarter ending 2025-12-31 was $5.34M, a 33.44% increase year-over-year.
- Lucid Diagnostics Inc. selling and marketing expense for the quarter ending 2025-09-30 was $4.29M, a 5.79% increase year-over-year.
- Lucid Diagnostics Inc. selling and marketing expense for fiscal 2025 was $17.71M, a 7.57% increase from fiscal 2024.
- Lucid Diagnostics Inc. selling and marketing expense for fiscal 2024 was $16.46M, a 0.36% increase from fiscal 2023.
- Lucid Diagnostics Inc. selling and marketing expense for fiscal 2023 was $16.40M, a 1.67% increase from fiscal 2022.
- Lucid Diagnostics Inc. selling and marketing expense for fiscal 2022 was $16.13M, a 206.73% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.78M 10-Q · filed 2026-08-12 | $10.78M 10-Q · filed 2026-08-12 | $16.12M derived: sum of 3 quarters · filed 2026-08-12 | $20.41M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $5.00M 10-Q · filed 2026-05-13 | $10.35M derived: sum of 2 quarters · filed 2026-05-13 | $14.64M derived: sum of 3 quarters · filed 2026-05-13 | $18.64M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $5.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $9.63M derived: sum of 2 quarters · filed 2026-03-25 | $13.64M derived: sum of 3 quarters · filed 2026-08-12 | $17.71M 10-K · filed 2026-03-25 |
| 2025-09-30 | $4.29M 10-Q · filed 2025-11-12 | $8.30M derived: sum of 2 quarters · filed 2026-08-12 | $12.37M 10-Q · filed 2025-11-12 | $16.37M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $4.01M 10-Q · filed 2026-08-12 | $8.08M 10-Q · filed 2026-08-12 | $12.08M derived: sum of 3 quarters · filed 2026-08-12 | $16.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $4.07M 10-Q · filed 2026-05-13 | $8.07M derived: sum of 2 quarters · filed 2026-05-13 | $12.13M derived: sum of 3 quarters · filed 2026-05-13 | $16.34M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $8.06M derived: sum of 2 quarters · filed 2026-03-25 | $12.27M derived: sum of 3 quarters · filed 2026-03-25 | $16.46M 10-K · filed 2026-03-25 |
| 2024-09-30 | $4.06M 10-Q · filed 2025-11-12 | $8.27M derived: sum of 2 quarters · filed 2025-11-12 | $12.46M 10-Q · filed 2025-11-12 | $16.87M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.21M 10-Q · filed 2025-08-12 | $8.40M 10-Q · filed 2025-08-12 | $12.81M derived: sum of 3 quarters · filed 2025-08-12 | $16.65M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $4.19M 10-Q · filed 2025-05-13 | $8.60M derived: sum of 2 quarters · filed 2025-05-13 | $12.44M derived: sum of 3 quarters · filed 2025-05-13 | $16.47M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $8.24M derived: sum of 2 quarters · filed 2025-03-24 | $12.28M derived: sum of 3 quarters · filed 2025-03-24 | $16.40M 10-K · filed 2025-03-24 |
| 2023-09-30 | $3.84M 10-Q · filed 2024-11-12 | $7.87M derived: sum of 2 quarters · filed 2024-11-12 | $12.00M 10-Q · filed 2024-11-12 | $17.01M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $4.03M 10-Q · filed 2024-08-12 | $8.16M 10-Q · filed 2024-08-12 | $13.17M derived: sum of 3 quarters · filed 2024-08-12 | $17.10M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $4.13M 10-Q · filed 2024-05-13 | $9.14M derived: sum of 2 quarters · filed 2024-05-13 | $13.07M derived: sum of 3 quarters · filed 2024-05-13 | $16.94M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $8.94M derived: sum of 2 quarters · filed 2024-03-25 | $12.82M derived: sum of 3 quarters · filed 2024-03-25 | $16.13M 10-K · filed 2024-03-25 |
| 2022-09-30 | $3.93M 10-Q · filed 2023-11-13 | $7.80M derived: sum of 2 quarters · filed 2023-11-13 | $11.12M 10-Q · filed 2023-11-13 | $13.75M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $3.87M 10-Q · filed 2023-08-14 | $7.19M 10-Q · filed 2023-08-14 | $9.82M derived: sum of 3 quarters · filed 2023-08-14 | $10.74M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $3.32M 10-Q · filed 2023-05-15 | $5.95M derived: sum of 2 quarters · filed 2023-05-15 | $6.87M derived: sum of 3 quarters · filed 2023-05-15 | $7.89M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $3.55M derived: sum of 2 quarters · filed 2023-03-14 | $4.57M derived: sum of 3 quarters · filed 2023-03-14 | $5.26M 10-K · filed 2023-03-14 |
| 2021-09-30 | $918.00K 10-Q · filed 2022-11-14 | $1.94M derived: sum of 2 quarters · filed 2022-11-14 | $2.63M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $1.02M 10-Q · filed 2022-08-15 | $1.71M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $689.00K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $1.30M 10-K · filed 2022-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Apyx Medical Corp (APYX) | United States | $0.120B | -21.85 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |